Technical Aspects of Fecal Microbial Transplantation (FMT)

被引：32
作者：
Bhutiani N. [1 ]
Schucht J.E. [1 ]
Miller K.R. [1 ]
McClave S.A. [2 ]
机构：
[1] Department of Surgery, Division of Trauma and Critical Care, University of Louisville, Louisville, KY
[2] Department of Medicine, Division of Gastroenterology, University of Louisville, 550 S. Jackson St., Ambulatory Care Building 3nd Floor, Louisville, 40202, KY
来源：
Current Gastroenterology Reports | 2018年 / 20卷 / 7期
关键词：
Dysbiosis; Fecal transplant;
D O I：
10.1007/s11894-018-0636-7
中图分类号：
学科分类号：
摘要：
Purpose of Review: Fecal microbial transplantation (FMT) has become established as an effective therapeutic modality in the treatment of antibiotic-refractory recurrent Clostridium difficile colitis. A number of formulations and methods of delivery of FMT are currently available, each with distinct advantages. This review aims to review donor and patient selection for FMT as well as procedural aspects of FMT to help guide clinical practice. Recent Findings: FMT can be obtained in fresh, frozen, lyophilized, and capsule-based formulations for delivery by oral ingestion, nasoenteric tube, colonoscopy, or enema (depending on the formulation used). Choosing the optimal method relies heavily on patient-related factors, including underlying pathology and severity of illness. As potential applications for FMT expand, careful donor screening and patient selection are critical to minimizing risk to patients and physicians. Summary: FMT represents an excellent therapeutic option for treatment of recurrent Clostridium difficile colitis and holds promise as a possible treatment modality in a variety of other conditions. The wide array of delivery methods allows for its application in various disease states in both the inpatient and outpatient setting. © 2018, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
相关论文
共 58 条
[1]  
de Groot P.F., Frissen M.N., de Clercq N.C., Nieuwdorp M., Fecal microbiota transplantation in metabolic syndrome: history, present and future, Gut Microbes, 8, 3, pp. 253-267, (2017)
[2]  
Krezalek M.A., DeFazio J., Zaborina O., Zaborin A., Alverdy J.C., The shift of an intestinal “microbiome” to a “pathobiome” governs the course and outcome of sepsis following surgical injury, Shock (Augusta, Ga.), 45, 5, (2016)
[3]  
Gopalakrishnan V., Spencer C., Nezi L., Et al., Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients, Science, 359, 6371, pp. 97-103, (2018)
[4]  
Gopalakrishnan V., Spencer C., Reuben A., Response to anti-PD-1 based therapy in metastatic melanoma patients is associated with the diversity and composition of the gut microbiome, AACR, (2017)
[5]  
Wargo J.A., Gopalakrishnan V., Spencer C., Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy, Proc Am Soc Clin Oncol, (2017)
[6]  
Wang Z.-K., Yang Y.-S., Chen Y., Yuan J., Sun G., Peng L.-H., Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease, World J Gastroenterol: WJG, 20, 40, pp. 14805-14820, (2014)
[7]  
Alverdy J.C., Chang E.B., The re-emerging role of the intestinal microflora in critical illness and inflammation: why the gut hypothesis of sepsis syndrome will not go away, J Leukoc Biol, 83, 3, pp. 461-466, (2008)
[8]  
Morowitz M.J., Babrowski T., Carlisle E.M., Olivas A., Romanowski K.S., Seal J.B., The human microbiome and surgical disease, Ann Surg, 253, 6, pp. 1094-1101, (2011)
[9]  
Morowitz M.J., Carlisle E.M., Alverdy J.C., Contributions of intestinal bacteria to nutrition and metabolism in the critically ill, Surgical Clinics, 91, 4, pp. 771-785, (2011)
[10]  
Medicine USNLo. Clinical trials: fecal microbiota transplantation.
123456